Infectious pseudovirions based on HIV show the morphology of the parent virus and a genome that is partially expressed in infected cells. The constructs are capable of a single round of infection. In this study, we generated vesicular stomatitis virus (VSV) glycoprotein (G) pseudotyped HIV-1-derived pseudovirions that contain a codonoptimized p17/p24 HIV-1 gag or the green fluorescent protein (GFP) gene as transgene. BALB/c mice were immunized in a DNA prime pseudovirion boost fashion. Immunization induced a Gag-specific antibody response, high titers of neutralizing antibodies directed against the VSV-G protein and a Gag-specific IFN-gamma-secreting cytotoxic T lymphocyte (CTL) response. CTL responses were induced by both structural proteins contained in the pseudovirion preparation and through expression of the transgene. Infection properties similar to those of live attenuated HIV and the immunogenicity observed make infectious pseudovirions valuable tools to further study the mechanism of immune stimulation in models of HIV infection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/aid.2006.22.1162 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Electron tomography visualization of HIV-1 virions trapped by fusion inhibitors to host cells in infected tissues.
J Virol
November 2024
Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, California, USA.
HIV-1 delivers its genetic material to infect a cell after fusion of the viral and host cell membranes, which takes place after the viral envelope (Env) binds host receptor and co-receptor proteins. Binding of host receptor CD4 to Env results in conformational changes that allow interaction with a host co-receptor (CCR5 or CXCR4). Further conformational rearrangements result in an elongated pre-hairpin intermediate structure in which Env is anchored to the viral membrane by its transmembrane region and to the host cell membrane by its fusion peptide.
View Article and Find Full Text PDFWHO International Standards for antibodies to HPV6 HPV11 HPV31 HPV33 HPV45 HPV52 and HPV58.
NPJ Vaccines
September 2024
Vaccine, Immunity, and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Previously established World Health Organization (WHO) International Standards (IS) for anti-HPV16 and HPV18 antibodies are used to harmonize results across human papillomavirus (HPV) serology assays. Here, we present an international collaborative study to establish ISs for antibodies against HPV6 (NIBSC code 19/298), HPV11 (20/174), HPV31 (20/176), HPV33 (19/290), HPV45 (20/178), HPV52 (19/296) and HPV58 (19/300). The candidate standards were prepared using sera from naturally infected individuals.
View Article and Find Full Text PDFElectron tomography visualization of HIV-1 virions trapped by fusion inhibitors to host cells in infected tissues.
bioRxiv
August 2024
Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, California, 91125, USA.
HIV-1 delivers its genetic material to infect a cell after fusion of the viral and host cell membranes, which takes place after the viral envelope (Env) binds host receptor and co-receptor proteins. Binding of host receptor CD4 to Env results in conformational changes that allow interaction with a host co-receptor (CCR5 or CXCR4). Further conformational rearrangements result in an elongated pre-hairpin intermediate structure in which Env is anchored to the viral membrane by its transmembrane region and to the host cell membrane by its fusion peptide.
View Article and Find Full Text PDFOmicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results.
Vaccines (Basel)
July 2024
Unidad de Investigación de Vacunas, Instituto de Investigación Sanitaria HM, 28938 Madrid, Spain.
(1) Background: The global coronavirus disease 2019 vaccination adapts to protect populations from emerging variants. This communication presents interim findings from the new Omicron XBB.1.
View Article and Find Full Text PDFFunctional Characterisation of Surfactant Protein A as a Novel Prophylactic Means against Oncogenic HPV Infections.
Int J Mol Sci
July 2024
International Centre for Genetic Engineering and Biotechnology (ICGEB), Observatory, Cape Town 7925, South Africa.
Human papillomavirus (HPV) infection poses a significant health challenge, particularly in low- and middle-income countries (LMIC), where limited healthcare access and awareness hinder vaccine accessibility. To identify alternative HPV targeting interventions, we previously reported on surfactant protein A (SP-A) as a novel molecule capable of recognising HPV16 pseudovirions (HPV16-PsVs) and reducing infection in a murine cervicovaginal HPV challenge model. Building on these findings, our current study aimed to assess SP-A's suitability as a broad-spectrum HPV-targeting molecule and its impact on innate immune responses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!